All In Biotech

Drug Trial Radar · NCT03903835

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Feb 1, 2019

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Karolinska InstitutetAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council; Kom Op Tegen Kanker; Janssen Pharmaceutica N.V., Belgium; AstraZeneca; Cancerfonden
First posted
Apr 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Patients in the control arm will receive standard of care following national guidelines. Patients in the experimental arm will be randomized to treatments based on a biomarker signature inferred from diagnostic tissue or liquid biopsy profiling. The predefined biomarker signatures are tumor properties or mutations in genes/pathways with previously demonstrated clinical validity (e.g. prognostic value or association with treatment response). The biomarker signatures are identified using a hybridisation capture gene panel specifically designed for prostate cancer.

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

  • Enzalutamide Oral CapsuleDrug

    Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

  • Abiraterone Oral TabletDrug

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • CarboplatinDrug

    Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].

  • Cabazitaxel 60 mg Solution for InjectionDrug

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • Docetaxel Injectable SolutionDrug

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • Radium Chloride Ra-223Drug

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • Niraparib plus Abiraterone acetate plus PrednisoneDrug

    Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.

  • Capivasertib plus DocetaxelDrug

    Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.

  • ApalutamideDrug

    Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

  • DarolutamideDrug

    Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) in mCRPCTime frame: Until progressive disease or 60 months from start of treatment, whatever occurs first.
  2. Progression free survival (PFS) in mHSPCTime frame: From date of treatment start until the date of first documentation of progression, assessed up to 60 months

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • OLV Ziekenhuis Aalst

    Aalst, Belgium · Recruiting

  • GZA Sint-Augustinus

    Antwerp, Belgium · Recruiting

  • AZ Sint-Jan AV

    Bruges, Belgium · Recruiting

  • AZ Sint-Lucas

    Bruges, Belgium · Recruiting

  • Ziekenhuis Oost-Limburg

    Genk, Belgium · Recruiting

  • University Hospital Ghent

    Ghent, Belgium · Recruiting

  • AZ Jan Palfijn Ziekenhuis

    Ghent, Belgium · Not yet recruiting

  • Jessa ziekenhuis

    Hasselt, Belgium · Recruiting

  • AZ Groeninge

    Kortrijk, Belgium · Recruiting

  • University Hospital Luik

    Liège, Belgium · Recruiting

  • AZ Damiaan

    Ostend, Belgium · Recruiting

  • VITAZ

    Sint-Niklaas, Belgium · Recruiting

  • Ålesund Sjukehus

    Ålesund, Norway · Not yet recruiting

  • Kreftsenter Kristiansand

    Kristiansand, Norway · Recruiting

  • Akershus Universitetssykehus

    Lørenskog, Norway · Recruiting

  • Stavanger Universitetssjukehus

    Stavanger, Norway · Recruiting

  • Universitetssykehuset Nord-Norge Tromsö

    Tromsø, Norway · Not yet recruiting

  • Södra Alvsborgs sjukhus

    Borås, Sweden · Recruiting

  • Länssjukhuset Ryhov - Onkologiska kliniken

    Jönköping, Sweden · Recruiting

  • Länssjukhuset

    Kalmar, Sweden · Recruiting

  • Centralsjukhuset Region Värmland

    Karlstad, Sweden · Recruiting

  • Universitetssjukhuset Örebro

    Örebro, Sweden · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

  • Capio St.Görans Hospital

    Stockholm, Sweden · Recruiting

  • Länssjukhuset Sundsvall Härnösand

    Sundsvall, Sweden · Recruiting

  • Norrlands Universitetssjukhus

    Umeå, Sweden · Recruiting

  • Akademiska sjukhuset

    Uppsala, Sweden · Recruiting

  • Hallands sjukhus Varberg

    Varberg, Sweden · Recruiting

  • Centrallasarettet Onkologkliniken

    Vaxjo, Sweden · Recruiting

  • Falu lasarett

    Falun, Region Dalarna, Sweden · Recruiting

  • St. Claraspital

    Basel, Switzerland · Recruiting

  • Universitätsspital Basel

    Basel, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.